Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 833 results for "novartis ag"

Novartis AG (NVS) Showing Support Near $101.95

Option-trade picking algorithms patented by found a trading opportunity with Novartis AG ("NVS) that should provide a 3.54% return in just 168 days. Sell one Jan. '16 ..., 1 day ago

Novartis receives FDA approval for basal cell carcinoma drug

Novartis AG has received the FDA approval for Odomzo 200mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma, or laBCC, which has recurred following surgery or radiation therapy, or those who are not candidates ...
 Individual.com2 days ago Novartis : partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd  4 Traders4 days ago Novartis Stiftung bestätigt neue Mitglieder des Stiftungsrats und Dr. Jörg Reinhardt als neuen Vorsitzenden  Quoteline6 days ago NOVARTIS : Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt  4 Traders6 days ago

FDA approves Odomza from Novartis for increasingly common skin cancer, basal cell carcinoma

EAST RUTHERFORD, N.J. A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval. Odomza (pronounced ah-DOMM'-zoh) was approved for patients whose cancer ...
 FOXBusiness.com1 week ago FDA OK's Odomza from Novartis for common skin cancer type  Investor's Business Daily1 week ago BRIEF-Novartis says FDA approves Odomzo to treat form of skin cancer  Reuters1 week ago FDA approves Novartis's advanced skin cancer drug  Sharenet1 week ago

Potential Novartis AG (NVS) Trade Has 3.84% Downside Protection

After MondayaEUR(TM)s trading in Novartis AG ("NVS) the option-trade picking algorithms that power's Artificial Intelligence Center uncovered a trade that offers a 2.42% ...
 Individual.com4 days ago Potential Novartis AG (NVS) Trade Targets 3.53% Return  Individual.com3 days ago

Novartis Q2 net income decreases

Novartis AG has reported that net income attributable to shareholders for the second quarter ended June 30, 2015 was $1.84 billion, or $0.75 per diluted share, compared to $2.55 billion, or $1.03 per diluted share, for the same quarter ended June ...
 Individual.com2 days ago Novartis AG net dips by 29% in Q2 to US$ 1,838 mn  PharmaBiz1 week ago NOVARTIS : Pressured by Dollar Strength  4 Traders1 week ago Novartis Q2 Profit Declines, Backs 2015 Outlook - Quick Facts  Nasdaq1 week ago

Novartis Gets Positive CHMP Opinion For Revolade For Treatment Of SAA

Novartis AG (NVS) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA adopted a positive opinion for Revolade (eltrombopag) for the treatment of adult patients with severe aplastic anemia or ...
 RTTNews.com1 week ago Novartis: Tafinlar, Mekinist Achieve EU, U.S. Regulatory Milestones  Nasdaq1 week ago

Novartis India's net declines by 6% in Q1

Novartis India, a Rs. 845 crore MNC, has posted lower net profit of Rs. 13.45 crore during the first quarter ended June 2015 as compared to Rs. 14.31 crore in the corresponding period of last year and EBDITA by 1.2 per cent to Rs. 21.48 crore from ...
 PharmaBiz1 week ago

European Stocks Little Changed as Norsk Hydro Offsets Novartis

(Bloomberg) -- European stocks were little changed as better-than-expected earnings from Norsk Hydro ASA offset lower profit from Novartis AG. The Stoxx Europe 600 Index added 0.1 percent to 407.04 at 8:21 a.m. in London. Shares rose for a ninth ...
 La Repubblica1 week ago European Stocks Are Little Changed Amid Earnings; Novartis Falls  La Repubblica1 week ago U.S. Stocks Slip on Earnings as Dollar Tumbles, Bonds Advance  Boe Report4 days ago

MorphoSys Gets Milestone Payment From Novartis In Blood Disorders Program

MorphoSys AG (MPSYY, MPSYF) announced Thursday that it has received a milestone payment from Swiss drug giant Novartis AG (NVS) in connection with the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of blood disorders. ...
 RTTNews.com1 week ago MorphoSys receives milestone payment from Novartis in blood disorders programme  PharmaBiz1 week ago

Novartis blocked from selling Neupogen copycat until September

Novartis AG unit Sandoz must wait until September to sell Zarxio, the first biosimiar drug approved in the United States and a copycat version of Amgen Inc's Neupogen, a U.S. appeals court said on Tuesday. Ruling in a patent infringement lawsuit ...
 Reuters1 week ago Novartis AG Thwarted From Selling Amgen's Neupogen Until September  BioSpace1 week ago Novartis AG (NVS) Thwarted From Selling Amgen (AMGN)'s Neupogen Until September 7/22/2015  ClinicSpace1 week ago Drugmaker Novartis blocked from selling Neupogen copycat until Sept 2  Reuters UK1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
Get updated on latest news & your favorite topics right in your inbox!
More     Less